-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, ObeZqQ81ZTkzd6k7HBaIrpDLx98OCj8Zai3zSyJZOVSkFiiTkh/9nNscK8Nrkknt kUBJYiy2lLiXubhJVlgSTQ== 0001171520-08-000552.txt : 20080905 0001171520-08-000552.hdr.sgml : 20080905 20080905162648 ACCESSION NUMBER: 0001171520-08-000552 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20080829 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20080905 DATE AS OF CHANGE: 20080905 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEMACARE CORP /CA/ CENTRAL INDEX KEY: 0000801748 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 953280412 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-15223 FILM NUMBER: 081058906 BUSINESS ADDRESS: STREET 1: 15350 SHERMAN WAY STREET 2: SUITE 350 CITY: VAN NUYS STATE: CA ZIP: 91406 BUSINESS PHONE: 818-226-1968 MAIL ADDRESS: STREET 1: 15350 SHERMAN WAY STREET 2: SUITE 350 CITY: VAN NUYS STATE: CA ZIP: 91406 8-K 1 eps3106.htm HEMACARE CORPORATION eps3106.htm


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of the earliest event reported):  August 29, 2008
 
HEMACARE CORPORATION
(Exact name of registrant as specified in its charter)
 
California
000-15223
95-3280412
(State or other jurisdiction
of incorporation or organization)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

15350 Sherman Way, Suite 350, Van Nuys, CA  91406
(Address of principal executive offices) (Zip Code)

(818) 226-1968
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
   
o
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
   
o
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
   
o
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 




 

 
 
 
 

Item 1.01.
 
Entry into a Material Definitive Agreement.
 

On August 29, 2008, HemaCare Corporation (the "Company") entered into a Settlement Agreement and Mutual General Release (the “Agreement”) with Joseph Mauro and Valentin Adia (“Mauro and Adia”).  On August 26, 2006, the Company purchased from Mauro and Adia all of the outstanding capital stock of Teragenix Corporation, which subsequently was renamed HemaCare BioScience, Inc. (“HemaBio”).  Mr. Mauro was named Division President and Mr. Adia was named Vice President, Business Development of HemaBio.  For a description of the terms of this acquisition and the employment arrangements of Mauro and Adia, see the Company’s Current Reports on Form 8-K filed with the Securities and Exchange Commission (“SEC”) on September 5 and November 15, 2006.
 
After the acquisition, HemaBio operated the Company’s Florida based research products business.  On November 2, 2007, Mauro and Adia resigned as officers of HemaBio.  The Board of Directors of HemaBio, in consultation with, and with the approval of, the Company’s Board of Directors, determined HemaBio’s business could not operate without senior management, and that the pathway to future profitability was unclear.  Therefore, the Board of Directors of HemaBio decided that it was in the best interest of HemaBio’s creditors to close all operations of HemaBio, effective November 5, 2007.  For a complete description of the resignations of Mauro and Adia, see the Company’s Current Report on Form 8-K filed with the SEC on November 7, 2007.
 
On December 4, 2007, HemaBio executed and delivered an Assignment for Benefit of Creditors, under Florida Statutes Section 727.101 et seq. (“Assignment”), assigning all of its assets to an assignee, who is responsible for taking possession of, protecting, preserving, and liquidating such assets and ultimately distributing the proceeds to creditors of HemaBio according to their priorities as established by Florida law.  For a complete description of the Assignment, see the Company’s Current Report on Form 8-K filed with the SEC on December 14, 2007.
 
Disputes arose between the Company and Mauro and Adia pertaining to the Company’s acquisition of HemaBio from Mauro and Adia, and their management of HemaBio after the acquisition.  The dispute led to the filing of a lawsuit against Mauro and Adia in the Los Angeles Superior Court (Case No. LC082173) (the “Lawsuit”).
 
The Agreement resolves the disputes, including those alleged in the Lawsuit. The Agreement provides for the mutual general release of all claims between the Company and Mauro and Adia in exchange for:  i) Mauro and Adia’s cancellation of promissory notes, and accrued interest, received from the Company as part of the HemaBio acquisition consideration; ii) return of 248,000 shares of the Company’s common stock received by Mauro and Adia as part of the HemaBio acquisition consideration; and iii) payment by Mauro and Adia of $50,000 to the Company.
 
The foregoing summary of the Agreement is qualified in its entirety by the form of Agreement attached hereto as Exhibit 99.1 and incorporated herein by reference.
 

 
 
 
 


 
Item 9.01.
 
Financial Statements and Exhibits
 
     
(d)
 
Exhibits
 
 
     
 
Exhibit No.
Description
 
99.1
 
Settlement Agreement and Mutual Release executed August 29, 2008, between HemaCare Corporation and Joseph Mauro and Valentin Adia.
 

 

 
 
 
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date:  September 5, 2008
 
HEMACARE CORPORATION
 
By    /s/ Robert S. Chilton    
Robert S. Chilton,
Executive Vice President and Chief Financial Officer

 

 
 
 
 

Exhibit Index
 
Exhibit No.
Description
99.1
 
Settlement Agreement and Mutual Release executed August 29, 2008, between HemaCare Corporation and Joseph Mauro and Valentin Adia.
 

 
EX-99.1 2 ex99-1.htm ex99-1.htm

Exhibit 99.1

 
SETTLEMENT AGREEMENT AND MUTUAL GENERAL RELEASE
 
This Settlement Agreement and Mutual General Release ("Agreement") is entered as of August 26, 2008 between HEMACARE CORPORATION (“HemaCare”) on the one hand and JOSEPH MAURO (“Mauro”) and VALENTIN ADIA (“Adia”) on the other hand, with reference to the following:
 
RECITALS
 
WHEREAS, in or around August 2006, HemaCare on the one hand and Mauro and Adia on the other hand, entered a Stock Purchase Agreement, which the parties amended in or around November, 2006 (“SPA”);
 
WHEREAS, pursuant to the SPA, HemaCare purchased all of Mauro’s and Adia’s issued and outstanding stock of Teragenix Corporation, a Florida corporation (“Teragenix”) which, after the transaction, became known as HemaCare BioScience, Inc. (“HemaCare BioScience”);
 
WHEREAS, as consideration for the purchase of the Teragenix stock, HemaCare, among other things, transferred to Mauro and Adia, 376,000 shares of HemaCare common stock.  Mauro and Adia currently have in their possession 248,000 shares of HemaCare common stock (“HemaCare Stock”).  HemaCare also delivered to Mauro and Adia promissory notes in the amount of $200,000 (“Promissory Notes”) (copies of the Promissory Notes are attached hereto as Exhibit “A”);
 
WHEREAS, disputes have arisen in connection with the SPA and the Promissory Notes;
 
WHEREAS, HemaCare filed a lawsuit against Mauro and Adia in the Los Angeles County Superior Court, bearing Case No. LC082173 (the “Lawsuit”), alleging causes of action against Mauro and Adia for fraudulent inducement, fraud and breach of contract;
 
WHEREAS, Mauro and Adia have alleged that HemaCare owes Mauro and Adia $200,000, plus interest, based on the amounts of the Promissory Notes;
 
WHEREAS, this Agreement is a compromise of the claims and liabilities alleged between the parties to this Agreement and shall not be construed as an admission of liability or wrongdoing by the parties or by any of the individuals or entities released in this Agreement; and
 
WHEREAS, the parties desire to fully and finally settle and resolve all disputes and differences which exist or may exist between them.
 
In consideration of the Recitals and covenants below, the parties agree as follows:
 
AGREEMENT
 
1.           No Admission of Liability.  The parties mutually acknowledge and agree that (i) the settlement, (ii) the delivery of this Agreement, (iii) the consideration provided for in this Agreement, and (iv) everything contained or omitted from this Agreement, shall not be interpreted or construed as an admission of liability.  Rather, this Agreement represents the settlement of disputed claims and the parties expressly deny any liability.

 
 
 
 

 
2.           Consideration.  As consideration for this Agreement, the receipt and sufficiency of which are hereby acknowledged, Mauro and Adia shall, simultaneously, with the execution of this Agreement: (i)  cancel the Promissory Notes and waive all payments, interest or other rights associated with the Promissory Notes; (ii) pay to HemaCare the following:  (a)  Mauro shall pay to HemaCare the amount of Twenty-Seven Thousand, Six-Hundred and Twenty-One Dollars and 88/100 ($27,621.88); and (b) Adia shall pay to HemaCare the amount of Twenty-Two Thousand, Three Hundred Seventy-Eight and 12/100 ($22,378.12); (iii) transfer to HemaCare all right, title and interest in and to the HemaCare Stock;
 
3.           Dismissal of the Lawsuit.  After receipt of this Agreement fully executed by Mauro and Adia and after Mauro and Adia provide to HemaCare all the consideration specified in paragraph 2 above, HemaCare agrees to dismiss the Lawsuit with prejudice and serve on Mauro and Adia a conformed copy of the dismissal.
 
4.           Releases by Mauro and Adia.  Effective on signing this Agreement, and with the exception of the obligations stated in this Agreement, Mauro and Adia, for themselves and for each of their respective representatives, heirs, agents, successors and assigns (collectively “Mauro and Adia Releasors”), irrevocably release and forever discharge HemaCare and each of its employees, affiliates, predecessors, successors, subsidiaries, agents, servants, officers, directors, principals, owners, stockholders, representatives, insurers, investors, members, attorneys, experts, parent and related companies, joint venturers, assigns and any and all of their associated, affiliated or related persons or entities of any type or nature whatsoever, whether current or former (collectively “Mauro’s and Adia’s Releasees”), of and from any and all claims, demands, damages, debts, liabilities, accounts, reckonings, obligations, costs, expenses, liens, actions and causes of action of every kind and nature whatsoever whether now known or unknown, suspected or unsuspected which the Mauro and Adia Releasors now have, own, or hold, or at any time heretofore ever had, owned or held, or could, shall or may hereafter have, own or hold including any claim under any rule, statute, regulation or local law (“Mauro’s and Adia’s Released Claims”).  Mauro and Adia acknowledge and agree that the term Mauro’s and Adia’s Released Claims includes, but is not limited to claims in connection with the Promissory Notes, the HemaCare Stock, the SPA, as well as any claim for contract (oral, written, implied in fact or implied in law) or tort, including alter ego or agency claims, or claims for interference, defamation, wrongful termination, infliction of emotional distress, discrimination, retaliation, fraud, misrepresentation, and any claim, lien, liability, matter, cause, fact, thing, act or omission whatsoever occurring or existing at any time to and including the date of this Agreement.
 
5.           Releases by HemaCare.  Effective on signing this Agreement, and with the exception of the obligations stated in this Agreement, HemaCare irrevocably releases and forever discharges Mauro and Adia of and from any and all claims, demands, damages, debts, liabilities, accounts, reckonings, obligations, costs, expenses, liens, actions and causes of action of every kind and nature whatsoever whether now known or unknown, suspected or unsuspected which HemaCare now has, owns, or holds, or at any time heretofore ever had, owned or held, or could, shall or may hereafter have, own or hold including any claim under any rule, statute, regulation or local law (“HemaCare’s Released Claims”).  HemaCare acknowledges and agrees that the term HemaCare’s Released Claims includes, but is not limited to claims alleged in the Lawsuit as well as any claim for contract (oral, written, implied in fact or implied in law) or tort, including claims for interference, fraud, misrepresentation, and any claim, lien, liability, matter, cause, fact, thing, act or omission whatsoever occurring or existing at any time to and including the date of this Agreement.

 
-2-
 
 

 
6.           Scope.  It is the parties’ intention in giving and accepting the consideration in this Agreement, and in executing this Agreement that this Agreement shall be a full and final release of all claims.  The parties acknowledge familiarity with Section 1542 of the Civil Code of the State of California which provides:
 
A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.
 
7.           Waiver and Acknowledgment.  The parties waive any right or benefit each has or may have under Section 1542, or under any similar law of similar effect in any jurisdiction, including under Florida law, to the full extent each may lawfully waive all such rights and benefits pertaining to the subject matter of this Agreement.  The parties acknowledge they may hereafter discover facts in addition to or different from those they now know or believe to be true with respect to the subject matter of this Agreement, and that it is their intention to fully and forever settle and release all disputes and differences, known or unknown, sus­pected or unsuspected, which do now exist, may exist or heretofore have existed and that in furtherance of such inten­tion the releases herein given shall be and remain in effect as full and complete general releases, notwithstanding the discovery or existence of any such additional or different facts.
 
8.           No Assignment.  The parties warrant and represent that neither they, nor anyone on their behalf, previously assigned or transferred or purported to assign or transfer to any person or entity not a party to this Agreement any claims released in this Agreement, or any part or portion thereof.  Specifically, Mauro and Adia warrant and represent that each of them is the sole owner of all rights, title and interests in and to the Promissory Notes and that their cancellation of the Promissory Notes eliminates all obligations in connection with the Promissory Notes.  Mauro and Adia further warrant and represent that each of them is the sole owner of all rights, title and interest in and to the HemaCare stock which they are hereby transferring to HemaCare.  Mauro and Adia further warrant and represent that they alone have full and complete authority to cancel the Promissory Notes and that no other individual or entity has any interest in the Promissory Notes or needs to provide consent in order to cancel the Promissory Notes.  Mauro and Adia acknowledge, however, that HemaCare BioScience filed an Assignment for the Benefit of Creditors, pursuant to Florida Statutes Section 727 et al. (“Assignee”).  Mauro and Adia agree that nothing in this Agreement is intended to cause a release of their claims filed with the Assignee or of any claims the Assignee may have against Mauro and Adia.  The parties acknowledge and agree that these warranties and representations are essen­tial and material terms of this Agreement without which none of the consideration received in connection herewith would have been made or delivered.  The foregoing warranties and rep­resentations shall survive the delivery of this Agreement, and the parties shall each indemnify and hold the other harmless from any claims, demands or actions which have been assigned or transferred, or purported to have been assigned or transferred, in violation of the foregoing repre­sentation and warranty, including all damages, attorneys’ fees and costs if there is a breach or purported breach of these representations and warranties.
 

 
-3-
 
 

 
a.           Agreement Explained.  The parties had the opportunity to obtain a complete explanation from legal counsel of their own choosing as to the meaning and legal effect of each term in this Agreement.  The parties entered into this Agreement with full knowledge as to the meanings and effects of this Agreement.
 
b.           No Actions or Proceedings.   Other than the Lawsuit there is no pending or threatened suit, proceeding or compliance review before any court, governmental agency, or arbitrator with respect to Mauro’s and Adia’s Released Claims or with respect to HemaCare’s Released Claims.  The parties agree to immediately dismiss with prejudice any such suit, proceeding or compliance review and provide proof of such dismissal immediately to the parties’ counsel.
 
c.           Actions By Third Parties.  The parties agree not to benefit from any lawsuit, administrative proceeding or compliance review brought by any other person or agency against any of the individuals and entities released in this Agreement, to the fullest extent of law.
 

HemaCare’s Notice Address:
Attention Sue Bendavid
Lewitt, Hackman, Shapiro, Marshall & Harlan
16633 Ventura Blvd.
Suite 1100
Encino, CA 91436

Mauro’s Notice Address:
12590 Little Palm Lane
Boca Raton, FL  33428

Adia’s Notice Address:
11001 Sunset Ridge Circle
Boynton Beach, FL  33473
 
11.        General Provisions.
 
a.           Law.  This Agreement shall be interpreted, enforced and governed under California law.
 
b.           Severability.  The provisions of this Agreement shall be severable.  If any provi­sion is held by an arbitrator or a court of competent jurisdiction to be unenforceable, in whole or in part, the remainder shall remain in effect and the stricken provision shall be replaced, to the extent possible, with an enforceable provision as similar in tenor as legally possible.

 
-4-
 
 

 
c.           Counterparts.  This Agreement may be signed by facsimile and in one or more counterparts, each of which shall be deemed an original instrument and together shall constitute the entire Agreement.
 
d.           Entire Agreement.  This is the entire Agreement of the parties relating to the transactions set forth herein, and all prior understandings, representations and statements, oral, written or implied, concerning this transaction are superseded by this Agreement.  No amendments will be valid unless written and signed by both parties.  The parties acknowledge they are not executing this Agreement in reli­ance on any oral promise, representation or warranty not contained herein.
 
e.           Binding on Heirs.  This Agreement shall inure to the benefit of and be binding upon the heirs, executors, administrators and legal successors of the parties hereto.
 
f.           Negotiated Agreement.  This Agreement is the result of negotiations between the parties.  Any ambiguity shall not be construed against either side on the basis of such side having drafted or prepared the language of any provision.
 
g.           Payments of Costs, Expenses, and Fees.  All costs and expenses incurred in negotiating this Agreement and in connection with the Lawsuit shall be borne by each party by themselves.  If any claim, controversy, dispute or legal action is brought in connection with the terms or conditions of this Agreement or for the enforcement of this Agreement, the prevailing party shall be entitled to recover reasonable attorneys' fees and costs incurred, in addition to any other relief to which they may be entitled, whether or not suit or arbitration is filed and whether or not any such suit or arbitration proceeds to judgment.
 
h.           Understood Agreement/Independent Counsel.  The parties acknowledge they read and understood this Agreement, in its entirety, and are voluntarily entering into this Agreement of their own free will, without duress or undue influence by any non-party or by any party to this Agreement.  The parties, and each of them, acknowledge, represent and warrant that they were represented by independent legal counsel of their own choice throughout all negotiations preceding and occurring in connection with the negotiation and execution of this Agreement.
 

 
Joseph Mauro
 
/s/ Joseph Mauro
 
HemaCare Corporation
 
/s/  Julian Steffenhagen         
 
By:  Julian Steffenhagen          
 
Its: Interim Chief Executive Officer  
 
Valentin Adia
 
/s/ Valentin Adia

 
-5-
 
 

-----END PRIVACY-ENHANCED MESSAGE-----